Extended Data Fig. 1: Glycolysis signatures are enriched in tumor-infiltrating T cells from larger tumors, both in mice treated with IgG control and in mice treated with anti-PD-1. | Nature Immunology

Extended Data Fig. 1: Glycolysis signatures are enriched in tumor-infiltrating T cells from larger tumors, both in mice treated with IgG control and in mice treated with anti-PD-1.

From: Deficiency of metabolic regulator PKM2 activates the pentose phosphate pathway and generates TCF1+ progenitor CD8+ T cells to improve immunotherapy

Extended Data Fig. 1

a, Gene set enrichment analysis using the KEGG Glycolysis / Gluconeogenesis dataset for differences in glycolytic gene signatures in tumor-infiltrating CD8 + T cells between: anti-PD-1-treated progressing (Group 3) and anti-PD-1-treated regressing (Group 2) tumors at early timepoints; anti-PD-1-treated progressing (Group 6) and anti-PD-1-treated regressing (Group 4) tumors at later timepoints; and anti-PD-1-treated progressing (Group 6) and anti-PD-1-treated partially regressing (Group 5) tumors at later timepoints. b, Heatmap showing normalized expression of selected genes from the KEGG Glycolysis / Gluconeogenesis dataset across groups. Numbers: (a-b) n = 3-8 biological replicates per group. Statistics: (a) GSEA by fgsea package in R.

Back to article page